SuperworthCytek Biosciences price to free cash flow CTKB
Market value divided by free cash flow over the last twelve months, since 2024.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 45.6×
- Oct 2025
- Peer median
- 22.4×
Cytek Biosciences' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.
It was last meaningful in Oct 2025, at 45.6×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2025 | 45.6× | 17.5× | 49.9× |
| 2024 | 28.6× | 26.6× | 495× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Cytek Biosciences' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| CTKBCytek Biosciences | n/m |
| NRCNRC Health | 22.4× |
| CDNACareDx | n/m |
| VCYTVeracyte | 23.2× |
| BLLNBillionToOne | 153× |
| ICCCImmucell | 22.1× |
| LNTHLantheus | 16.8× |
| Peer median | 22.4× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Cytek Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.